EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantitative HBsAg Distribution and Eligibility for Cure-Directed Bepirovirsen Therapy in Chronic Hepatitis B

Jakob Groß, Lukas Middendorf, Sven Pischke, Ioannis Belios, Kilian Keetz, Lisa Sophie Pflüger, Ansgar Lohse, Marc Lütgehetmann, Julian Schulze zur Wiesch

Viruses · 13.11.2026 · 18 (11) · 1261

DOI: 10.3390/v18111261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 13.11.2026. Verfasst von Jakob Groß und 8 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, iDfellows: Hamburg Clinician Scientist Programme in Infectious Diseases, DZIF.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bepirovirsen achieved a functional cure in 19–20% of nucleos(t)ide analogue (NUC)-treated participants in the phase 3 B-Well trials. These trials enrolled patients with baseline quantitative hepatitis B surface antigen (qHBsAg) levels >100–≤ 3000 IU/mL, but the potential reach of this treatment in routine care remains uncertain. We evaluated 706 patients with chronic hepatitis B monoinfection at a German tertiary-care center. qHBsAg levels were ≤100, >100–≤1000, >1000–≤3000, and >3000 IU/mL in 145/706 (20.5%), 175/706 (24.8%), 142/706 (20.1%), and 244/706 (34.6%) patients, respectively. Overall, 317/706 (44.9%) patients fell within the B-Well qHBsAg window. Of these, 109/317 (34.4%) were receiving NUC therapy; among the remaining 208 untreated patients, 23/208 (11.1%) met an operationalized EASL 2025 indication for NUC initiation. The primary implementation scenario therefore comprised 132/706 (18.7%) patients. Excluding patients with identifiable B-Well trial exclusion proxies in a sensitivity analysis reduced this number to 102/706 (14.4%). Applying stratum-specific B-Well response rates of 26.0% and 7.3% yielded hypothetical functional cure rates of 17.2% (approximately 23 modeled functional cures) in the primary scenario and 16.1% (approximately 16 modeled functional cures) in the restricted scenario. These findings estimate the potential clinical reach of bepirovirsen and associated hypothetical functional cure outcomes at our center, highlighting the absence of current NUC therapy as a key factor limiting its implementation.

Förderung

  • German Research Foundation
  • iDfellows: Hamburg Clinician Scientist Programme in Infectious Diseases
  • DZIF
  • EU Horizon program
  • Deutsches Zentrum für Infektionsforschung

Zitieren

APA

Groß, J., Middendorf, L., Pischke, S., Belios, I., Keetz, K., Pflüger, L. S., Lohse, A., Lütgehetmann, M., & Wiesch, J. S. Z. (2026). Quantitative HBsAg Distribution and Eligibility for Cure-Directed Bepirovirsen Therapy in Chronic Hepatitis B. Viruses, 18(11), 1261. https://doi.org/10.3390/v18111261

Vancouver

Groß J, Middendorf L, Pischke S, Belios I, Keetz K, Pflüger LS, et al. Quantitative HBsAg Distribution and Eligibility for Cure-Directed Bepirovirsen Therapy in Chronic Hepatitis B. Viruses. 2026;18(11):1261. doi:10.3390/v18111261

BibTeX
@article{Gro2026,
  author = {Groß, Jakob and Middendorf, Lukas and Pischke, Sven and Belios, Ioannis and Keetz, Kilian and Pflüger, Lisa Sophie and Lohse, Ansgar and Lütgehetmann, Marc and Wiesch, Julian Schulze zur},
  title = {Quantitative HBsAg Distribution and Eligibility for Cure-Directed Bepirovirsen Therapy in Chronic Hepatitis B},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1261},
  doi = {10.3390/v18111261}
}
Kostenlos starten →